Evaluation of programmed cell death ligand-1 expression in primary central nervous system lymphoma using whole-tumor histogram analysis of multiparametric MRI: implications for immunotherapy selection

利用多参数磁共振成像的全肿瘤直方图分析评估原发性中枢神经系统淋巴瘤中程序性死亡配体-1的表达:对免疫治疗选择的意义

阅读:1

Abstract

OBJECTIVE: To assess the diagnostic performance of whole-tumor histogram analysis of multiparametric MRI in predicting programmed cell death ligand-1 (PD-L1) expression in primary central nervous system lymphoma (PCNSL). METHODS: A total of 130 patients with PCNSL (61 males, aged 21-80 years) were included in the study. Histogram features derived from T2-weighted imaging (T2WI), T1-weighted imaging (T1WI), fluid-attenuated inversion recovery (FLAIR), contrast-enhanced T1-weighted imaging (T1WI+C), and apparent diffusion coefficient (ADC) were compared between the low and high PD-L1 expression groups using the Mann-Whitney U test. Receiver operating characteristic (ROC) curves and logistic regression analysis were applied to assess the diagnostic performance of both individual and combined models in predicting PD-L1 expression levels in PCNSL. RESULTS: Eighteen histogram features extracted from multiparametric MRI exhibited significant differences between high and low PD-L1 expression in PCNSL (all P < 0.05). The predictive performance of single-sequence models was relatively modest, with areas under the curve (AUC) ranging from 0.637 to 0.705, and no significant differences were observed between these models (all P > 0.05). The combined model demonstrated the highest diagnostic performance (AUC = 0.809), significantly outperforming the single-sequence models (all P < 0.05). CONCLUSIONS: Whole-tumor histogram analysis of multiparametric MRI shows potential as a non-invasive method for evaluating PD-L1 expression in PCNSL, which may assist in the identification of immunotherapy-eligible patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。